% alzhub.org library filter
% Source: https://alzhub.org/research?category=mci&design=trial
% 6 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{ornish2024-38849944,
  author  = {Ornish, D. and Madison, C. and Kivipelto, M. and Kemp, C. and McCulloch, C. E. and Galasko, D. and Artz, J. and Rentz, D. and others},
  title   = {{Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01482-z},
  pmid    = {38849944},
  url     = {https://doi.org/10.1186/s13195-024-01482-z}
}

@article{wang2019-31488882,
  author  = {Wang, X. and Sun, G. and Feng, T. and Zhang, J. and Huang, X. and Wang, T. and Xie, Z. and Chu, X. and others},
  title   = {{Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression}},
  journal = {Cell research},
  year    = {2019},
  doi     = {10.1038/s41422-019-0216-x},
  pmid    = {31488882},
  url     = {https://doi.org/10.1038/s41422-019-0216-x}
}

@article{tariot2018-29955659,
  author  = {Tariot, P. N. and Lopera, F. and Langbaum, J. B. and Thomas, R. G. and Hendrix, S. and Schneider, L. S. and Rios-Romenets, S. and Giraldo, M. and others},
  title   = {{The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2018},
  doi     = {10.1016/j.trci.2018.02.002},
  pmid    = {29955659},
  url     = {https://doi.org/10.1016/j.trci.2018.02.002}
}

@article{cummings2023-37251912,
  author  = {Cummings, J. and Zhou, Y. and Lee, G. and Zhong, K. and Fonseca, J. and Cheng, F.},
  title   = {{Alzheimer's disease drug development pipeline: 2023}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2023},
  doi     = {10.1002/trc2.12385},
  pmid    = {37251912},
  url     = {https://doi.org/10.1002/trc2.12385}
}

@article{dickerson2013-24130528,
  author  = {Dickerson, B. C. and Wolk, D. A. and {Alzheimer's Disease Neuroimaging Initiative}},
  title   = {{Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau}},
  journal = {Frontiers in aging neuroscience},
  year    = {2013},
  doi     = {10.3389/fnagi.2013.00055},
  pmid    = {24130528},
  url     = {https://doi.org/10.3389/fnagi.2013.00055}
}

@article{yu2025-40840993,
  author  = {Yu, Congcong and Yang, Huijie and Zhang, Bing and Chen, Shihua and Yang, Sijue and Li, Fangyi and Zhu, Wenhui and Zhai, Beibei and others},
  title   = {{Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase}},
  journal = {BMJ Open},
  year    = {2025},
  doi     = {10.1136/bmjopen-2024-095382},
  pmid    = {40840993},
  url     = {https://doi.org/10.1136/bmjopen-2024-095382}
}